Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk

Rosenstock, Julio; Perkovic, Vlado; Erik Johansen, Odd; E. Cooper, Mark; E. Kahn, Steven; Marx, Nikolaus; H. Alexander, John; Pencina, Michael; D. Toto, Robert; Wanner, Christoph; Zinman, Bernard; J. Woerle, Hans; Baanstra, David; Pfarr, Egon; Schnaidt, Sven; Meinicke, Thomas; T. George, Jyothis; von Eynatten, Maximilian; K. McGuire, Darren; the CARMELINA Investigators, for

doi:10.1001/jama.2018.18269

Public

Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk

Published in JAMA • Nov 12, 2018

Authors:

Julio Rosenstock

Vlado Perkovic

Odd Erik Johansen

Abstract

Importance: Type 2 diabetes is associated with increased cardiovascular (CV) risk. Prior trials have demonstrated CV safety of 3 dipeptidyl peptidase 4 (DPP-4) inhibitors but have included limited numbers of patients with high CV risk and chronic kidney disease. Objective: To evaluate the effect of ...

Subject

Medicine

Linagliptin

Type 2 diabetes

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!